Wound Care Biologics Market By Product (Biological Skin Substitutes, Topical Agents), By Wound Type (Acute Wound, Chronic Wound), By End User (Hospitals and Clinics, Wound Centers and Burn Centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
The wound care biologics market was valued at $1.8 billion in 2022 and is estimated to reach $3.3 billion by 2032, exhibiting a CAGR of 6.1% from 2023 to 2032. Wound care biologics refers to a category of advanced medical products that are derived from biological sources or manufactured using biotechnology processes. These wound care biologics products are designed for healing and management of various types of wounds, such as acute and chronic wounds. In addition, wound care biologics products consist of extracellular matrix, growth factors, cellular components, or skin substitutes that mimic or supplement the body's natural healing processes. Biologic products such as biological skin substitutes and topical agents are used in the wound healing process by tissue regeneration and by reducing inflammation.
The wound care biologics market has experienced significant growth owing to the increase in prevalence of chronic wounds, such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers, which is a major factor that fosters the wound care biologics market growth. For instance, according to National Diabetes Statistics Report by Centers for Disease Control and Prevention (CDC), 2022, about 37.3 million people are diabetic in the U.S. As the number of people with diabetes continues to grow, so does the risk of developing diabetic foot ulcers, leading to higher demand for effective treatment options including wound care biologics.
In addition, elderly individuals are more prone to chronic wounds thus, the rise in geriatric population drives the demand for wound care biologics and propels market growth. These advanced therapies provide efficient wound healing to this vulnerable population. Moreover, traditional wound care products such as hydrocolloids, hydrogels, film & foam dressings, and alginates are being increasingly replaced with advanced wound care products such as biologics, due to their enhanced effectiveness in managing wounds by enabling rapid healing, which further supports the market growth.
Furthermore, research and development efforts have led to the introduction of innovative wound care biologics with enhanced efficacy and safety profiles. The introduction of novel growth factors, stem cell-based therapies, and tissue-engineered products have expanded the treatment options available, driving market growth. For instance, Organogenesis Holding Inc. company has developed and commercialized a product called Apligraf, which is an advanced tissue-engineered therapydesigned for the treatment of chronic wounds. Such advanced products available in the market drive the market growth.
In addition, ongoing research in the field of regenerative medicine, exploring the potential of stem cells, growth factors, and tissue engineering to promote wound healing further support the market growth This surge in investment in research and development activities by pharmaceutical companies, academic institutions, and healthcare organizations has accelerated the discovery of novel therapeutic approaches, fueling the growth of the market.
The wound care biologics market is segmented on the basis of product, wound type, end user, and region. By product, the market is bifurcated into biological skin substitutes and topical agents. The biological skin substitutes segment further classified into human donor tissue derived products, animal derived products, and cell based bioengineered products. By wound type, the market is categorized into acute and chronic. The acute segment is further classified into burns & trauma, and surgical. The chronic segment is further divided into pressure ulcers, diabetic ulcers, venous ulcers, and others. By end user, the market is segregated into hospitals and clinics, wound centers and burn centers, and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Major key players that operate in the wound care biologics market are ConvaTec Group plc, Integra LifeSciences Holdings Corporation, Kerecis, Lavior Pharma Inc., MIMEDX Group, Inc., Organogenesis Holding Inc., Skye Biologics Holdings, LLC, Smith & Nephew plc, Stryker Corporation., Tissue Regenix Group Plc. Key players have adopted product launch, product approval, and acquisition as key developmental strategies to improve the product portfolio of the wound care biologics market.
Key Benefits For StakeholdersThis report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the wound care biologics market analysis from 2022 to 2032 to identify the prevailing wound care biologics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the wound care biologics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global wound care biologics market trends, key players, market segments, application areas, and market growth strategies.
Key Market SegmentsBy Wound TypeAcute Wound
Type
Burns and Trauma
Surgical
Chronic Wound
Type
Pressure Ulcer
Diabetic Ulcer
Venous Ulcer
Others
By End UserHospitals and Clinics
Wound Centers and Burn Centers
Others
By ProductBiological Skin Substitutes
Type
Human Donor Tissue Derived Products
Animal Derived Products
Cell Based Bioengineered Products
Topical Agents
By RegionNorth America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Skye Biologics Holdings, LLC
Tissue Regenix Group Plc
Lavior Pharma Inc.
ORGANOGENESIS HOLDINGS INC.
Kerecis
Smith & Nephew plc
Stryker Corporation.
MIMEDX Group, Inc.
Integra LifeSciences Holdings Corporation
ConvaTec Group plc
Please Note: It will take 7-10 business days to complete the report upon order confirmation.